REGULATORY

Moderna’s BA.4/5 COVID Jab Up for PAFSC Review on Oct. 31

October 25, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A key Japanese health ministry panel will review Moderna’s bivalent COVID-19 booster vaccine tailored to the BA.4/BA.5 Omicron variants at its meeting on October 31. The new vaccine was filed by Moderna early this month under a procedure to partially…

To read the full story

Moderna Files BA.4/5-Tailored COVID-19 Vaccine in Japan
October 5, 2022

REGULATORY

US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
May 26, 2026
CEA Review Group Holds First Meeting, Technical Debate Yet to Begin
May 26, 2026
AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
May 26, 2026
Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…